Inactive Instrument

Navidea Biopharmaceuticals Inc Stock price Nyse

Equities

US63937X1037

Biotechnology & Medical Research

Sales 2021 532K Sales 2022 65.65K Capitalization 6.78M
Net income 2021 -11M Net income 2022 -15M EV / Sales 2021 50.2 x
Net cash position 2021 3.48M Net Debt 2022 440K EV / Sales 2022 110 x
P/E ratio 2021
-2.5 x
P/E ratio 2022
-0.38 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 63.91%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Director of Finance/CFO 58 23-07-27
Chief Tech/Sci/R&D Officer - 20-12-31
General Counsel - 22-03-31
Members of the board TitleAgeSince
Director/Board Member 47 22-09-29
Director/Board Member 69 21-07-07
Director/Board Member 46 23-05-31
More insiders
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of undetected disease. The Company's business is focused on two primary types of drug products, such as diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform, and therapeutic development programs, including therapeutic applications of its Manocept platform. It has developed processes for producing the first four therapeutic Manocept immuno-construct series, the Manocept doxorubicin (MAN-DOX) series, which is designed to specifically target and kill or modify activated CD206+ macrophages by delivering doxorubicin, a Manocept paclitaxel series (MAN-PAC), and a Manocept Bisphosphonate series (MAN-BIS).
More about the company
  1. Stock
  2. Equities
  3. Stock Navidea Biopharmaceuticals, Inc.
  4. Stock Navidea Biopharmaceuticals Inc - Nyse